Related Experiment Video
Updated: Oct 4, 2025
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
ECONOMIC BURDEN OF MULTIPLE SCLEROSIS IN GEORGIA
D Gugutsidze1, D Gigineishvili1, M Kiziria1
11Javakhishvili Tbilisi State University, Department of Neurology and Neurosurgery; 2Sarajishvili Institute of Neurology, Tbilisi; Georgia.
Abstract:
The purpose of this study is to estimate economic burden of multiple sclerosis in Georgia and to compare costs of patients with different course of disease and disability level. Hospital-based cohort study was conducted in the P.Sarajishvili Institute of Neurology and Medical Center Pineo to estimate direct medical costs in patients with MS treated between 2019-2020. The mean annual direct medical cost for MS patient on disease-modifying therapies (DMTs) was statistically higher than for non-DMTs patient and estimated as 23254.7Lari[7382.5$] (SD 9026.3; CIs:21133.7-25375.8) versus 1429.1lari [453.6 $] (SD 861.7, CIs; 1309.5-1548.6) (P<0.0001). MS places a huge economic burden on healthcare model and society in Georgia. DMTs are the main driver of cost.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...